136 related articles for article (PubMed ID: 36413758)
1. Availability of aldo-keto reductase 1C3 and ATP-binding cassette B1 as therapeutic targets for alleviating paclitaxel resistance in breast cancer MCF7 cells.
Matsunaga T; Horinouchi M; Saito H; Hisamatsu A; Iguchi K; Yoshino Y; Endo S; Ikari A
J Biochem; 2023 Mar; 173(3):167-175. PubMed ID: 36413758
[TBL] [Abstract][Full Text] [Related]
2. Development of cisplatin resistance in breast cancer MCF7 cells by up-regulating aldo-keto reductase 1C3 expression, glutathione synthesis and proteasomal proteolysis.
Kobayashi M; Yonezawa A; Takasawa H; Nagao Y; Iguchi K; Endo S; Ikari A; Matsunaga T
J Biochem; 2022 Jan; 171(1):97-108. PubMed ID: 34676395
[TBL] [Abstract][Full Text] [Related]
3. Roles of aldo-keto reductases 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Matsunaga T; Saito H; Endo S; Iguchi K; Soda M; El-Kabbani O; Hara A; Ikari A
Free Radic Res; 2016 Dec; 50(12):1296-1308. PubMed ID: 27629782
[TBL] [Abstract][Full Text] [Related]
4. Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Matsunaga T; Okumura N; Saito H; Morikawa Y; Suenami K; Hisamatsu A; Endo S; Ikari A
Chem Biol Interact; 2020 Dec; 332():109295. PubMed ID: 33096057
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells.
Matsunaga T; Kawabata S; Yanagihara Y; Kezuka C; Kato M; Morikawa Y; Endo S; Chen H; Iguchi K; Ikari A
Chem Biol Interact; 2019 Dec; 314():108839. PubMed ID: 31563593
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Matsunaga T; Yamaji Y; Tomokuni T; Morita H; Morikawa Y; Suzuki A; Yonezawa A; Endo S; Ikari A; Iguchi K; El-Kabbani O; Tajima K; Hara A
Free Radic Res; 2014 Nov; 48(11):1371-85. PubMed ID: 25156503
[TBL] [Abstract][Full Text] [Related]
8. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Li W; Zhai B; Zhi H; Li Y; Jia L; Ding C; Zhang B; You W
Tumour Biol; 2014 Sep; 35(9):8883-91. PubMed ID: 24894670
[TBL] [Abstract][Full Text] [Related]
9. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
10. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
[TBL] [Abstract][Full Text] [Related]
11. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
13. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment.
He S; Chu X; Wu Y; Jiang J; Fang P; Chen Y; Liu Y; Qiu Z; Xiao Y; Li Z; Pan D; Zhang Q; Xie H; Xing S; Feng F; Liu W; Guo Q; Zhao L; Yang P; Sun H
J Med Chem; 2023 Jul; 66(14):9537-9560. PubMed ID: 37409679
[TBL] [Abstract][Full Text] [Related]
14. Instability of C154Y variant of aldo-keto reductase 1C3.
Endo S; Takada S; Honda RP; Müller K; Weishaupt JH; Andersen PM; Ludolph AC; Kamatari YO; Matsunaga T; Kuwata K; El-Kabbani O; Ikari A
Chem Biol Interact; 2017 Oct; 276():194-202. PubMed ID: 28025170
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
16. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
Morell A; Budagaga Y; Vagiannis D; Zhang Y; Laštovičková L; Novotná E; Haddad A; Haddad M; Portillo R; Hofman J; Wsól V
Arch Toxicol; 2022 Dec; 96(12):3265-3277. PubMed ID: 35972551
[TBL] [Abstract][Full Text] [Related]
18. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
[TBL] [Abstract][Full Text] [Related]
19. In silico study of novel alpha tocopheroids as effective inhibitors of aldo-keto reductase 1c3 (AKR1C3) enzyme.
Basu T; Upadhyay AK
J Biomol Struct Dyn; 2023 Aug; ():1-15. PubMed ID: 37534497
[TBL] [Abstract][Full Text] [Related]
20. Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2.
Cai J; Chen S; Zhang W; Hu S; Lu J; Xing J; Dong Y
Phytomedicine; 2014 Jun; 21(7):984-91. PubMed ID: 24680370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
